DEBATE: Should all MS patients be treated with statins? YES SEE also CON View and COMMENTARY
New Players in MS
October 30, 2010
The copyright for all illustrations and pictures has been heeded by all authors to the best of their knowledge. If you feel your copyright has been infringed in any way or if you have any questions, do contact us by clicking on this link, please.
|Congress:||The 4th World Congress on Controversies in Neurology (CONy)|
3-Hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors, ‘statins’ are widely used oral cholesterol-lowering drugs. Statins competitively inhibit HMG-CoA reductase, the enzyme that catalyzes conversion of HMG-CoA to L-mevalonate, a key intermediate in cholesterol synthesis. Some metabolites of mevalonate are also involved in posttranslational modification of specific proteins involved in cell proliferation and differentiation. Thus, statins have important biologic effects independent of their cholesterol-reducing properties. Recent studies in animal models of multiple sclerosis (MS) indicate that statins have anti-inflammatory and neuroprotective properties.
|Category:||Neurology; Multiple Sclerosis; treatment; statins;|